EA201992328A1 - Фармацевтическая композиция, содержащая ленватиниба мезилат - Google Patents

Фармацевтическая композиция, содержащая ленватиниба мезилат

Info

Publication number
EA201992328A1
EA201992328A1 EA201992328A EA201992328A EA201992328A1 EA 201992328 A1 EA201992328 A1 EA 201992328A1 EA 201992328 A EA201992328 A EA 201992328A EA 201992328 A EA201992328 A EA 201992328A EA 201992328 A1 EA201992328 A1 EA 201992328A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
composition containing
lenvatiniba
mesilate
lenvatinib mesylate
Prior art date
Application number
EA201992328A
Other languages
English (en)
Inventor
Луис Ногейрас Ньето
Лисардо Альварес Фернандес
Хосе Велада Кальсада
Рохит Кумар
Original Assignee
Синтон Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58489241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201992328(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Синтон Б.В. filed Critical Синтон Б.В.
Publication of EA201992328A1 publication Critical patent/EA201992328A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Abstract

Настоящее изобретение относится к фармацевтической композиции, содержащей терапевтически эффективную дозу ленватиниба мезилата, содержащей натрий, где массовое соотношение ленватиниба мезилата к карбонатам натрия находится в диапазоне от 1:1,5 до 1:5.
EA201992328A 2017-04-04 2018-04-04 Фармацевтическая композиция, содержащая ленватиниба мезилат EA201992328A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17164761.3A EP3384901A1 (en) 2017-04-04 2017-04-04 Pharmaceutical composition comprising lenvatinib mesylate
PCT/EP2018/058629 WO2018185175A1 (en) 2017-04-04 2018-04-04 Pharmaceutical composition comprising lenvatinib mesylate

Publications (1)

Publication Number Publication Date
EA201992328A1 true EA201992328A1 (ru) 2020-02-14

Family

ID=58489241

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992328A EA201992328A1 (ru) 2017-04-04 2018-04-04 Фармацевтическая композиция, содержащая ленватиниба мезилат

Country Status (6)

Country Link
US (1) US11911509B2 (ru)
EP (2) EP3384901A1 (ru)
EA (1) EA201992328A1 (ru)
ES (1) ES2923214T3 (ru)
PT (1) PT3606511T (ru)
WO (1) WO2018185175A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10583133B2 (en) 2018-03-12 2020-03-10 Shilpa Medicare Limited Pharmaceutical compositions of lenvatinib
PT3632436T (pt) * 2018-10-04 2022-07-22 Synthon Bv Composição farmacêutica compreendendo sais de lenvatinib
CN111053772A (zh) * 2018-10-16 2020-04-24 四川科伦药物研究院有限公司 一种乐伐替尼的药物组合物及其用途
WO2021240281A1 (en) * 2020-05-23 2021-12-02 Shilpa Medicare Limited Oral liquid formulations of lenvatinib
EP4147689A1 (en) 2021-09-13 2023-03-15 Lotus Pharmaceutical Co., Ltd. Lenvatinib formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
BRPI0418200A (pt) 2003-12-25 2007-04-17 Eisai Co Ltd forma cristalina do sal de 4-(3-cloro-4-(ciclopropilaminocarbonila) aminofenóxi)-7-metóxi-6-quinolinacarboxamida ou o solvato do sal e um processo para a sua preparação
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
WO2006084474A2 (en) 2005-02-10 2006-08-17 Lifecycle Pharma A/S A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor
JP5209966B2 (ja) 2005-09-01 2013-06-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 崩壊性の改善された医薬組成物の製造方法
MX344927B (es) 2009-08-19 2017-01-11 Eisai R&D Man Co Ltd Composición farmacéutica que contiene derivado de quinolina.
WO2017028660A1 (zh) * 2015-08-17 2017-02-23 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物或其盐的药物组合物
DE102015215604A1 (de) 2015-08-17 2017-02-23 Schaeffler Technologies AG & Co. KG Stufenlos verstellbares Getriebe (CVT) mit elektronischem Drehmomentfühler, Antriebstrang und Verfahren zum Steuern / Regeln eines stufenlosen Getriebes

Also Published As

Publication number Publication date
EP3606511A1 (en) 2020-02-12
US11911509B2 (en) 2024-02-27
EP3384901A1 (en) 2018-10-10
EP3606511B1 (en) 2022-04-20
PT3606511T (pt) 2022-07-22
WO2018185175A1 (en) 2018-10-11
US20200188380A1 (en) 2020-06-18
ES2923214T3 (es) 2022-09-26

Similar Documents

Publication Publication Date Title
EA201992328A1 (ru) Фармацевтическая композиция, содержащая ленватиниба мезилат
MX2019001096A (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
PH12018500377A1 (en) Novel annelated benzamides
EA201992542A1 (ru) Фармацевтическая композиция для местного применения, содержащая, по меньшей мере, амитриптилин, для лечения периферической нейропатической боли
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
PH12018500378A1 (en) Novel annelated phenoxyacetamides
MX2017011978A (es) Analogos deuterados de etifoxina, sus derivados y usos de estos.
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
EA201791009A1 (ru) Композиции, содержащие циклоспорин
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
CY1123185T1 (el) Παραγωγα ινδολιου
EA201990162A1 (ru) Фармацевтические композиции
EA201892837A1 (ru) Физиологически сбалансированные составы для инъекций, включающие фоснетупитант
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
EA202190339A1 (ru) Пиридопиримидины в качестве ингибиторов н4-гистаминовых рецепторов